Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hamilton Lane INCHLNE · Entity 3823 | Director · 10% owner | September 16, 2026 | September 18, 2026 |
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | October 07, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hamilton Lane INC
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 977 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 977 · Balance 977 F1: Represents the number of shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's Amended and Restated 2017 Equity Incentive Plan in consideration of the reporting person's service on the board of directors of the Issuer. The shares vest one year from the transaction date. |
| Class B Common StockSEC Table I · non-derivative | Direct | 600,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 600,000 F2: The Issuer Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. |
| Class B UnitsSEC Table II · derivative / convertible security | IndirectSee footnote | 600,000 |
Reported balance
Holding disclosure · report date 2026-09-16 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 600,000 F3: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4: These securities are owned directly by HLA Investments, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's Amended and Restated 2017 Equity Incentive Plan in consideration of the reporting person's service on the board of directors of the Issuer. The shares vest one year from the transaction date.
F2: The Issuer Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote.
F3: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date.
F4: These securities are owned directly by HLA Investments, LLC.
PTC THERAPEUTICS, INC.
Report date October 07, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,294,094 |
Last balance in matching sequence
After 2026-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-10-07 · Sale · Disposed 2,447 · Balance 1,294,147 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.89 to $63.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Row 3 · 2026-10-07 · Sale · Disposed 53 · Balance 1,294,094 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F3: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 163,266 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 163,266 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026.
F2: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.89 to $63.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 9, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 53 | $63.95 | $3,389.35 |
DisclosureSEC source: 0001288952-26-000014 · form4-10092026_051001.xml · nonDerivative · entry 3 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,294,094 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| October 07, 2026 Filed Oct 9, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,447 | $63.38 | $155,090.86 |
DisclosureSEC source: 0001288952-26-000014 · form4-10092026_051001.xml · nonDerivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,294,147 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $62.89 to $63.88 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 376 | $68.45 | $25,737.20 |
DisclosureSEC source: 0001288952-26-000012 · form4-09182026_050902.xml · nonDerivative · entry 5 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,296,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.35 to $68.84 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 17, 2026 Filed Sep 18, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,624 | $67.83 | $652,795.92 |
DisclosureSEC source: 0001288952-26-000012 · form4-09182026_050902.xml · nonDerivative · entry 4 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,296,970 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.27 to $68.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 20:38 UTC | Hamilton Lane INC HLNE · Entity 3823 | GrantClass A Common Stock | 977 | $0.00 | $0.00 |
DisclosureSEC source: 0001288952-26-000011 · wk-form4_1789763906.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 977 F1 · shares: Represents the number of shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's Amended and Restated 2017 Equity Incentive Plan in consideration of the reporting person's service on the board of directors of the Issuer. The shares vest one year from the transaction date. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,006 | $67.35 | $471,854.10 |
DisclosureSEC source: 0001288952-26-000012 · form4-09182026_050902.xml · nonDerivative · entry 3 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,306,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.99 to $67.72 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 16, 2026 Filed Sep 18, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,994 | $66.58 | $199,340.52 |
DisclosureSEC source: 0001288952-26-000012 · form4-09182026_050902.xml · nonDerivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,313,600 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.99 to $66.96 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 10,000 | $67.34 | $673,400.00 |
DisclosureSEC source: 0001288952-26-000008 · form4-09112026_050901.xml · nonDerivative · entry 3 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,316,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.84 to $67.66 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 572 | $68.67 | $39,279.24 |
DisclosureSEC source: 0001288952-26-000008 · form4-09112026_050901.xml · nonDerivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,326,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $68.54 to $68.76 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| September 09, 2026 Filed Sep 11, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,428 | $67.79 | $639,124.12 |
DisclosureSEC source: 0001288952-26-000008 · form4-09112026_050901.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,327,166 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $67.54 to $68.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 17:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 610 | $72.22 | $44,054.20 |
DisclosureSEC source: 0001288952-26-000006 · form4-08282026_050802.xml · nonDerivative · entry 5 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,336,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.11 to $72.25 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 27, 2026 Filed Aug 28, 2026 17:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 11,890 | $71.55 | $850,729.50 |
DisclosureSEC source: 0001288952-26-000006 · form4-08282026_050802.xml · nonDerivative · entry 4 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,337,204 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $70.94 to $71.92 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 17:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,626 | $73.18 | $411,710.68 |
DisclosureSEC source: 0001288952-26-000006 · form4-08282026_050802.xml · nonDerivative · entry 3 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,349,094 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $73.02 to $73.40 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 26, 2026 Filed Aug 28, 2026 17:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,874 | $72.74 | $500,014.76 |
DisclosureSEC source: 0001288952-26-000006 · form4-08282026_050802.xml · nonDerivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,354,720 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.02 to $73.01 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 691 | $72.92 | $50,387.72 |
DisclosureSEC source: 0001288952-26-000004 · form4-08212026_050801.xml · nonDerivative · entry 6 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,361,594 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026 F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.60 to $73.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,390 | $71.88 | $171,793.20 |
DisclosureSEC source: 0001288952-26-000004 · form4-08212026_050801.xml · nonDerivative · entry 5 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,362,285 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026 F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $71.50 to $72.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 9,419 | $70.78 | $666,676.82 |
DisclosureSEC source: 0001288952-26-000004 · form4-08212026_050801.xml · nonDerivative · entry 4 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,364,675 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026 F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $70.50 to $71.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,165 | $73.67 | $527,845.55 |
DisclosureSEC source: 0001288952-26-000004 · form4-08212026_050801.xml · nonDerivative · entry 3 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,374,094 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026 F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $73.33 to $74.02 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 5,335 | $72.86 | $388,708.10 |
DisclosureSEC source: 0001288952-26-000004 · form4-08212026_050801.xml · nonDerivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Indirect · See footnote Disclosed balance after: 1,381,259 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by Section Six Partners, L.P., of which the Reporting Person is a general partner and limited partner, on May 14, 2026 F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $72.33 to $73.32 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. F3 · ownership.nature: Represents shares of common stock held by Section Six Partners, L.P. The Reporting Person is a general and limited partner of Section Six Partners, L.P. The Reporting Person disclaims beneficial ownership of the shares of common stock held by Section Six Partners, L.P. except to the extent of his pecuniary interest therein. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 6,950 | $0.00 Strike: $76.74 | $0.00 |
DisclosureSEC source: 0001288952-26-000002 · form4-01062026_050106.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,950 Underlying: Common Stock · 6,950 shares Expires 2036-01-01 F2 · derivative.exercise_date: This option was granted on January 2, 2026 and vests over one year in twelve equal monthly installments, commencing on February 2, 2026. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001288952-26-000002 · form4-01062026_050106.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,266 F1 · shares: Restricted stock units granted on January 2, 2026 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 2, 2026 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 2, 2027. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001288952-25-000004 · form4-12182025_051201.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Currently exercisable. Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 24,000 | $30.86 | $740,640.00 |
DisclosureSEC source: 0001288952-25-000004 · form4-12182025_051201.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,266 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:25 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 25,005 | $146.51 | $3,663,482.55 |
DisclosureSEC source: 0001433642-25-000096 · wk-form4_1757366734.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 600,000 Underlying: Class A Common Stock · 25,005 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement (the "Exchange Agreement") entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering. At the Issuer's election, the exchange was settled in cash. F3 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · ownership.nature: These securities are owned directly by HLA Investments, LLC. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:25 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 25,005 | $0.00 | $25.01 |
DisclosureSEC source: 0001433642-25-000096 · wk-form4_1757366734.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,000 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement (the "Exchange Agreement") entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering. At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Issuer Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:35 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 100,000 | $159.00 | $15,900,000.00 |
DisclosureSEC source: 0001628280-25-005774 · wk-form4_1739568927.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 625,005 Underlying: Class A Common Stock · 100,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement (the "Exchange Agreement") entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering. At the Issuer's election, the exchange was settled in cash. F3 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · ownership.nature: These securities are owned directly by HLA Investments, LLC. Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:35 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 100,000 | $0.00 | $100.00 |
DisclosureSEC source: 0001628280-25-005774 · wk-form4_1739568927.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,005 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement (the "Exchange Agreement") entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering. At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 17,600 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001022 · form4-01072025_050115.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-01-02 F2 · derivative.exercise_date: This option was granted on January 3, 2025 and vests over one year in twelve equal monthly installments, commencing on February 3, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001022 · form4-01072025_050115.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,266 F1 · shares: Restricted stock units granted on January 3, 2025 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 17, 2025 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 3, 2026. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004133 · form4-02162024_040204.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-02-14 F2 · derivative.exercise_date: This option was granted on February 15, 2024 and vests over one year in twelve equal monthly installments, commencing on March 15, 2024. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 21:25 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004133 · form4-02162024_040204.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,266 F1 · shares: Restricted stock units granted on February 15, 2024 that vest over one year, with one-third (1/3) of the shares underlying the RSUs vesting on June 18, 2024 and the remaining two-thirds (2/3) of the original shares underlying the RSUs vesting on February 15, 2025. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:10 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,500 | $27.81 | $41,715.00 |
DisclosureSEC source: 0001415889-24-000919 · form4-01102024_090117.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,266 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023, to satisfy tax obligations in connection with the vesting of 4,664 restricted stock units from a January 5, 2023 grant of 8,000 restricted stock units. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,000 | $44.86 | $44,860.00 |
DisclosureSEC source: 0001415889-23-009501 · form4-06092023_080626.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,766 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 24, 2023, to satisfy tax obligations in connection with the vesting of 3,334 restricted stock units from a January 5, 2023 grant of 8,000 restricted stock units. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:27 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000682 · form4-01092023_090154.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-01-04 F2 · derivative.exercise_date: This option was granted on January 5, 2023 and vests over one year in twelve equal monthly installments, commencing on February 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:27 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-000682 · form4-01092023_090154.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,766 F1 · shares: Restricted stock units granted on January 5, 2023 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 6, 2023 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 5, 2024. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 24,000 | $0.00 Strike: $38.10 | $0.00 |
DisclosureSEC source: 0001179110-22-000391 · edgar.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: This option was granted on January 7, 2022 and vests over one year in twelve equal monthly installments, commencing on February 7, 2022. Read SEC document |
| January 07, 2022 Filed Jan 11, 2022 21:13 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-000391 · edgar.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,766 F1 · shares: Restricted stock units granted on January 7, 2022 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2022 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 7, 2023. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:40 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 27,000 | $87.36 | $2,358,720.00 |
DisclosureSEC source: 0001433642-21-000028 · wf-form4_161524322818350.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 725,005 Underlying: Class A Common Stock · 27,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F3 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · ownership.nature: These securities are owned directly by HLA Investments, LLC Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 22:40 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 27,000 | $0.00 | $27.00 |
DisclosureSEC source: 0001433642-21-000028 · wf-form4_161524322818350.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725,005 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 20,000 | $0.00 Strike: $66.49 | $0.00 |
DisclosureSEC source: 0001179110-21-000458 · edgar.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-05 F2 · derivative.exercise_date: This option was granted on January 6, 2021 and vests over one year in twelve equal monthly installments, commencing on February 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 8, 2021 22:03 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-000458 · edgar.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,366 F1 · shares: Restricted stock units ("RSUs") granted on January 6, 2021 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 8, 2021 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 6, 2022. Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 21:43 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 50,000 | $70.18 | $3,509,000.00 |
DisclosureSEC source: 0001433642-20-000123 · wf-form4_159968779415667.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 752,005 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F3 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · ownership.nature: These securities are owned directly by HLA Investments, LLC Read SEC document |
| September 04, 2020 Filed Sep 9, 2020 21:43 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001433642-20-000123 · wf-form4_159968779415667.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 752,005 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:48 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 50,000 | $70.09 | $3,504,500.00 |
DisclosureSEC source: 0001433642-20-000079 · wf-form4_159173569081950.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 802,005 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F3 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F3 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · ownership.nature: These securities are owned directly by HLA Investments, LLC Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:48 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001433642-20-000079 · wf-form4_159173569081950.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 802,005 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 21:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | PurchaseCommon Stock | 10,000 | $32.48 | $324,846.00 |
DisclosureSEC source: 0001070081-20-000068 · wf-form4_158456549581372.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,066 Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:39 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right To Buy) · Derivative | 20,000 | $0.00 Strike: $51.16 | $0.00 |
DisclosureSEC source: 0001070081-20-000046 · wf-form4_158050677833503.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-28 F2 · derivative.exercise_date: This option was granted on January 29, 2020 and vests over one year in twelve equal monthly installments, commencing on February 29, 2020. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:39 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 3,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001070081-20-000046 · wf-form4_158050677833503.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,066 F1 · kind: Restricted stock units ("RSUs") granted on January 29, 2020 that vest over one year, with five-twelfths (5/12) of the shares underlying the RSUs vesting on June 10, 2020 and the remaining seven-twelfths (7/12) of the original shares underlying the RSUs vesting on January 29, 2021. The Reporting Person has elected to defer receipt of all vested shares until the earliest to occur of (i) four years from the date of grant and (ii) the earliest to occur of (a) the date that is six months following separation of service from the Issuer, (b) a change in control event and (c) death. Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:52 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Units · Derivative | 50,000 | $60.01 | $3,000,500.00 |
DisclosureSEC source: 0001433642-19-000135 · wf-form4_156867072941884.xml · derivative · entry 2 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 852,005 Underlying: Class A Common Stock · 50,000 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F4 · derivative.exercise_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F4 · derivative.expiration_date: Pursuant to the Exchange Agreement, the Class B Units of Hamilton Lane Advisors, L.L.C. are exchangeable, on a one-for-one basis, for shares of Class A common stock or, at the Issuer's election, for cash. Upon exchange of a Class B Unit, the corresponding share of Class B common stock will be redeemed at par value and cancelled. The Class B Units do not have an expiration date. F3 · ownership.nature: These securities are owned directly by HLA Investments, LLC Read SEC document |
| September 12, 2019 Filed Sep 16, 2019 21:52 UTC | Hamilton Lane INC HLNE · Entity 3823 | OtherClass B Common Stock | 50,000 | $0.00 | $50.00 |
DisclosureSEC source: 0001433642-19-000135 · wf-form4_156867072941884.xml · nonDerivative · entry 1 SCHMERTZLER MICHAEL · CIK 0001288952 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 852,005 F1 · kind: The reporting person exchanged Class B Units (and corresponding shares of Class B common stock) with the Issuer pursuant to an exchange agreement entered into at the time of and in connection with a reorganization incident to the Issuer's initial public offering (the "Exchange Agreement"). At the Issuer's election, the exchange was settled in cash. F2 · balance_after: The Class B common stock does not carry economic value beyond the right to receive the par value of such stock upon liquidation, dissolution or exchange of those shares. However, the Class B common stock entitles its holder to ten votes per share on every matter submitted to the Issuer's stockholders for a vote. F3 · ownership.nature: These securities are owned directly by HLA Investments, LLC Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.